CDK4 and acute lymphoblastic leukemia: Recent studies showed a good synergistic effect in the combined use of the CDK4/6 inhibitor LEE-01 (ribociclib) with RAD001 and glucocorticoids in the treatment of T-ALL and B-cell ALL (B-ALL) (NCT03328104) [134].